

Wednesday, October 31st, 2018

SIMPLIFIED TENDER OFFER

For the shares of



Initiated by



Presented by

ALANTRA

NOTICE OF AVAILABILITY OF THE OFFEROR'S PROSPECTUS AND OTHER INFORMATION RELATING IN PARTICULAR TO THE LEGAL, FINANCIAL AND ACCOUNTING CHARACTERISTICS OF SANGAMO THERAPEUTICS

Offer price: 2.58 Euro per TxCell share
Offer duration: 17 trading days

This press release has been prepared and published by Sangamo Therapeutics Inc. in accordance with articles 231-27 2° and 231-28 I of the general regulations of the Financial Markets Authority (*Autorité des Marchés Financiers* - the "AMF").

Important Notice

In accordance with article L. 433-4 III of the French monetary and financial code and articles 237-14 et seq. of the general regulations of the AMF, in the event that, upon closure of the Offer, the number of shares not presented to the Offer by minority shareholders of TxCell does not represent more than 5% of the capital or voting rights of TxCell, Sangamo Therapeutics Inc. intends to implement, within three months of the close of the offer, a squeeze-out procedure in order that the shares not tendered to the Offer are transferred to it (with the exception of TxCell shares subject to a liquidity mechanism) subject to a compensation equal to the Offer price of 2.58 Euro per share.

In accordance with article L. 621-8 of the monetary and financial code and article 231-23 of its general regulations, the AMF has, in application of its declaration of conformity of the simplified tender offer dated 30 October 2018, affixed the visa No. 18-500 on 30 October 2018 on the offer document prepared by Sangamo Therapeutics relating to the simplified public tender offer for the TxCell shares issued or to be

issued and which are not currently held by Sangamo Therapeutics Inc. or not subject to a liquidity mechanism (the "Offer").

In accordance with the provisions of article 231-28 I of the general regulations of the AMF, the document concerning other information relating in particular to legal, financial and accounting characteristics of Sangamo Therapeutics, was filed with the AMF on 30 October 2018 and made available to the public as of today.

The Offer document prepared by Sangamo Therapeutics Inc. and approved by the AMF is available on the website of the AMF (www.amf-france.org) and of Sangamo Therapeutics Inc. (www.sangamo.com) and is made available to the public free of charge at Alantra Capital Markets, 6 rue Lamennais, 75008 Paris.

The other information document concerning in particular the legal, financial and accounting characteristics of Sangamo Therapeutics is available on the website of the AMF (www.amf-france.org) and of Sangamo Therapeutics Inc. (www.sangamo.com) and is made available to the public free of charge at Alantra Capital Markets, 6, rue Lamennais, 75008 Paris.

The Offer is made exclusively in France.

This press release, the information notice and all other documents in relation to the Offer do not constitute an offer with a view to selling or acquiring financial instruments or a solicitation of an offer in whatever country where this type of offer or solicitation would be illegal or to someone to whom such an offer could not be validly made. The Offer is not and will not be subject to any procedures or any registration or approval outside of France. TxCell shareholders who are resident in any country other than France may only participate in the Offer on the condition that such participation is authorised by the local law to which they are subject.

The dissemination or distribution of this press release, the information notice and all other documents relating to the Offer and participation in the Offer may be subject to legal restrictions in certain jurisdictions.

Persons in possession of this press release or the Offer documents must keep themselves abreast of the applicable legal restrictions and respect them. Non-adherence to these legal restrictions may constitute a violation of laws and regulations applicable to stock exchange transactions in certain jurisdictions. Sangamo Therapeutics takes no responsibility in the event of breach of the applicable legal restrictions by any person.